Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Anti-Müllerian Hormone and Its Clinical Use in Pediatrics with Special Emphasis on Disorders of Sex Development

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Osteoporosis Is Associated with Deteriorating Clinical Status in Adults with Cystic Fibrosis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Amino Acid Signatures to Evaluate the Beneficial Effects of Weight Loss

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Normal sweat secretion despite impaired growth hormone-insulin-like growth factor-I axis in obese subjects

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Evaluation of Serum Insulin-like Factor 3 Quantification by LC-MS/MS as a Biomarker of Leydig Cell Function

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Use of stored serum in the study of time trends and geographical differences in exposure of pregnant women to phthalates

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Increases in bioactive IGF do not parallel increases in total IGF-I during growth hormone treatment of children born SGA

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer
Using measurements of circulating anti-Müllerian hormone (AMH) in diagnosing and managing reproductive disorders in pediatric patients requires thorough knowledge on normative values according to age and gender. We provide age- and sex-specific reference ranges for the Immunotech assay and conversion factors for the DSL and Generation II assays. With this tool in hand, the pediatrician can use serum concentrations of AMH when determining the presence of testicular tissue in patients with bilaterally absent testes or more severe Disorders of Sex Development (DSD). Furthermore, AMH can be used as a marker of premature ovarian insufficiency (POI) in both Turner Syndrome patients and in girls with cancer after treatment with alkylating gonadotoxic agents. Lastly, its usefulness has been proposed in the diagnosis of polycystic ovarian syndrome (PCOS) and ovarian granulosa cell tumors and in the evaluation of patients with hypogonadotropic hypogonadism.
OriginalsprogEngelsk
TidsskriftInternational Journal of Endocrinology
Vol/bind2013
Sider (fra-til)198698
ISSN1687-8337
DOI
StatusUdgivet - 2013

ID: 42807139